Literature DB >> 24632749

Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Junwei Li1, Maria T Arévalo1, Yanping Chen1, Olivia Posadas1, Jacob A Smith1, Mingtao Zeng1.   

Abstract

Frequent mutation of influenza viruses keep vaccinated and non-vaccinated populations vulnerable to new infections, causing serious burdens to public health and the economy. Vaccination with universal influenza vaccines would be the best way to effectively protect people from infection caused by mismatched or unforeseen influenza viruses. Presently, there is no FDA approved universal influenza vaccine. In this study, we expressed and purified a fusion protein comprising of influenza matrix 2 protein ectodomain peptides, a centralized influenza hemagglutinin stem region, and cholera toxin subunit B. Vaccination of BALB/c mice with this novel artificial antigen resulted in potent humoral immune responses, including induction of specific IgA and IgG, and broad protection against infection by multiple influenza viruses. Furthermore, our results demonstrated that when used as a mucosal antigen, cholera toxin subunit B improved antigen-stimulated T cell and memory B cell responses.

Entities:  

Keywords:  broad spectrum vaccine; cholera toxin subunit B; influenza; intranasal vaccination; protective immunity

Mesh:

Substances:

Year:  2014        PMID: 24632749      PMCID: PMC4896531          DOI: 10.4161/hv.28407

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  51 in total

1.  The decision to get vaccinated against influenza.

Authors:  Pedram Sendi; Rebecca Locher; Bruno Bucheli; Manuel Battegay
Journal:  Am J Med       Date:  2004-06-15       Impact factor: 4.965

Review 2.  New horizons in adjuvants for vaccine development.

Authors:  Steven G Reed; Sylvie Bertholet; Rhea N Coler; Martin Friede
Journal:  Trends Immunol       Date:  2008-12-06       Impact factor: 16.687

3.  Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.

Authors:  Christine B Turley; Richard E Rupp; Casey Johnson; David N Taylor; Julie Wolfson; Lynda Tussey; Uma Kavita; Lawrence Stanberry; Alan Shaw
Journal:  Vaccine       Date:  2011-05-30       Impact factor: 3.641

4.  Inhibition of fusion activity of influenza A haemagglutinin mediated by HA2-specific monoclonal antibodies.

Authors:  E Varecková; V Mucha; S A Wharton; F Kostolanský
Journal:  Arch Virol       Date:  2003-03       Impact factor: 2.574

Review 5.  Toward a universal influenza virus vaccine: prospects and challenges.

Authors:  Natalie Pica; Peter Palese
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

6.  Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.

Authors:  Masanori Isaka; Yanqiu Zhao; Eri Nobusawa; Setsuko Nakajima; Katsuhisa Nakajima; Yoko Yasuda; Hideyuki Matsui; Tadao Hasegawa; Jun-Ichi Maeyama; Kazunori Morokuma; Kunio Ohkuma; Kunio Tochikubo
Journal:  Microbiol Immunol       Date:  2008-02       Impact factor: 1.955

7.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Adjuvant solution for pandemic influenza vaccine production.

Authors:  Christopher H Clegg; Richard Roque; Neal Van Hoeven; Lucy Perrone; Susan L Baldwin; Joseph A Rininger; Richard A Bowen; Steven G Reed
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-08       Impact factor: 11.205

9.  Universal influenza DNA vaccine encoding conserved CD4+ T cell epitopes protects against lethal viral challenge in HLA-DR transgenic mice.

Authors:  Jeff Alexander; Pamuk Bilsel; Marie-France del Guercio; Stephani Stewart; Aleksandra Marinkovic-Petrovic; Scott Southwood; Claire Crimi; Lo Vang; Les Walker; Glenn Ishioka; Vivek Chitnis; Alessandro Sette; Erika Assarsson; Drew Hannaman; Jason Botten; Mark J Newman
Journal:  Vaccine       Date:  2009-11-04       Impact factor: 3.641

Review 10.  Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development.

Authors:  Zuzana Staneková; Eva Varečková
Journal:  Virol J       Date:  2010-11-30       Impact factor: 4.099

View more
  8 in total

1.  A dual purpose universal influenza vaccine candidate confers protective immunity against anthrax.

Authors:  Maria T Arévalo; Junwei Li; Diana Diaz-Arévalo; Yanping Chen; Ashley Navarro; Lihong Wu; Yongyong Yan; Mingtao Zeng
Journal:  Immunology       Date:  2016-12-05       Impact factor: 7.397

2.  Generation of a safe and effective live viral vaccine by virus self-attenuation using species-specific artificial microRNA.

Authors:  Junwei Li; Maria T Arévalo; Diana Diaz-Arévalo; Yanping Chen; Jang-Gi Choi; Mingtao Zeng
Journal:  J Control Release       Date:  2015-04-07       Impact factor: 9.776

3.  Nasal aluminum (oxy)hydroxide enables adsorbed antigens to induce specific systemic and mucosal immune responses.

Authors:  Haiyue Xu; Tinashe B Ruwona; Sachin G Thakkar; Yanping Chen; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2017-09-21       Impact factor: 3.452

Review 4.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 5.  Noninvasive vaccination against infectious diseases.

Authors:  Zhichao Zheng; Diana Diaz-Arévalo; Hongbing Guan; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

6.  Intranasal Vaccination With Lipoproteins Confers Protection Against Pneumococcal Colonisation.

Authors:  Franziska Voß; Thomas P Kohler; Tanja Meyer; Mohammed R Abdullah; Fred J van Opzeeland; Malek Saleh; Stephan Michalik; Saskia van Selm; Frank Schmidt; Marien I de Jonge; Sven Hammerschmidt
Journal:  Front Immunol       Date:  2018-10-18       Impact factor: 7.561

7.  The Nontoxic Cholera B Subunit Is a Potent Adjuvant for Intradermal DC-Targeted Vaccination.

Authors:  Laura Antonio-Herrera; Oscar Badillo-Godinez; Oscar Medina-Contreras; Araceli Tepale-Segura; Alberto García-Lozano; Lourdes Gutierrez-Xicotencatl; Gloria Soldevila; Fernando R Esquivel-Guadarrama; Juliana Idoyaga; Laura C Bonifaz
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

8.  Intranasally administered protein coated chitosan nanoparticles encapsulating influenza H9N2 HA2 and M2e mRNA molecules elicit protective immunity against avian influenza viruses in chickens.

Authors:  Irshad Ahmed Hajam; Amal Senevirathne; Chamit Hewawaduge; Jehyoung Kim; John Hwa Lee
Journal:  Vet Res       Date:  2020-03-06       Impact factor: 3.683

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.